Exchange Traded Concepts’s CorMedix CRMD Stock Holding History

Exchange Traded Concepts’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-38	Closed	–	–	1032
2020 Q3	$0	Buy	+38	New	+$191	﹤0.01%	919

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Exchange Traded Concepts's CRMD Position: Q4 2020 in Review

Exchange Traded Concepts sold out of CorMedix (CRMD) in Q4 2020, closing a stake of 38 shares.

Exchange Traded Concepts first reported a position in CRMD in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 75 funds tracked by Wall St. Rank hold CRMD as of Q4 2020.

Exchange Traded Concepts reported no remaining CorMedix position as of Q4 2020 after selling out during the quarter.
Exchange Traded Concepts sold 38 CorMedix shares in Q4 2020.
Exchange Traded Concepts first reported a position in CorMedix in Q3 2020 and held it in 1 quarter.
Exchange Traded Concepts's CorMedix position peaked at $0 in Q3 2020.
75 funds tracked by Wall St. Rank held CorMedix as of Q4 2020.

Based on Exchange Traded Concepts's 13F filing for Q4 2020, filed 19 Jan 2021.